Related Experiment Videos
beta-Funaltrexamine (beta-FNA) and neural tumor response in mice
Abstract:
The effects of beta-FNA, a highly selective and irreversible mu opioid receptor antagonist, in altering tumor response in A/Jax mice inoculated with S20Y cells were determined. Inoculation of neuroblastoma cells in control subjects resulted in 100% tumor incidence within 16 days, and mean and median survival times of 36 and 35 days, respectively, following tumor inoculation. Tumor incidence and survival times were comparable to controls for mice given chronic injections of 2 mg/kg and 10 mg/kg beta-FNA every 48 h beginning 2 days after tumor inoculation. Tumor growth was subnormal in the 10 mg/kg beta-FNA group. Both dosages of beta-FNA were found to block morphine-induced analgesia for 48 h. These results suggest that, in and by themselves, mu receptors selectively antagonized by beta-FNA do not play an important role in neuro-oncogenic events.
Insights
Beta-funaltrexamine (beta-FNA), a mu opioid receptor antagonist, did not significantly alter neuroblastoma tumor incidence or survival in mice. However, higher doses did show subnormal tumor growth and blocked morphine analgesia.
Area of Science:
- Neuro-oncology
- Pharmacology
- Cancer Research
Background:
- Neuroblastoma is a pediatric cancer.
- Mu opioid receptors are involved in various physiological processes.
- Selective antagonists can be used to study receptor function.
Purpose of the Study:
- To investigate the role of mu opioid receptors in neuroblastoma tumor development.
- To determine if beta-funaltrexamine (beta-FNA) affects tumor incidence, growth, or survival.
- To assess the pharmacological effects of beta-FNA on pain pathways.
Main Methods:
- A/Jax mice were inoculated with S20Y neuroblastoma cells.
- Mice received chronic injections of beta-FNA (2 mg/kg or 10 mg/kg) every 48 hours.
- Tumor incidence, growth, and survival times were monitored.
- Morphine-induced analgesia was assessed to confirm beta-FNA's antagonist activity.
Main Results:
- Control mice showed 100% tumor incidence within 16 days and a median survival of 35 days.
- Beta-FNA treatment did not significantly alter tumor incidence or survival times compared to controls.
- Subnormal tumor growth was observed in the 10 mg/kg beta-FNA group.
- Both dosages of beta-FNA effectively blocked morphine-induced analgesia for 48 hours.
Conclusions:
- Mu opioid receptors, when selectively antagonized by beta-FNA, do not appear to play a significant role in neuroblastoma oncogenesis.
- Beta-FNA is a potent and long-lasting mu opioid receptor antagonist.
- Further research may explore other opioid receptor subtypes or signaling pathways in neuroblastoma.